Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

4D Medical (ASX:4DX) could become the next Pro Medicus, and its taken some important strides in 2025!

There's not many Australian radiology companies that seek to conquer the USA, but 4D Medical (ASX:4DX) is one of them. Another one was Pro Medicus (ASX:PME), and everyone knows how that story turned out - that stock is now worth over $11bn, all because of runaway success in the US market. 4D Medical shareholders inevitably…

ByNick SundichSeptember 2, 2025

ASX stocks in America: Here are 4 performing well and 4 performing poorly

You might think ASX stocks in America are doing better than peers which are not there because the USA is a much bigger market. In reality, this is not always the case. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] ASX stocks in America: Here are 4 performing…

ByNick SundichSeptember 2, 2025

Blinklab (ASX:BB1): Is this exciting company the next ResApp?

Blinklab (ASX:BB1) is the answer to the question of how you could help children with autism - a response that begins with 'there's an app for that'. There is precedent for app-based health companies to succeed, just look at ResApp (ASX:RAP), which was bought by Pfizer for $179m back in 2022. The former chairman of that…

ByNick SundichAugust 29, 2025

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Nova Eye Medical (ASX:EYE) is no clinical stage medtech company, but has just an exciting 12 months ahead as if it was a clinical stage company with company-making catalysts ahead. Because even though it has commercialised its devices, a major 12 months are ahead during which it is expected to make major inroads in the US…

ByNick SundichAugust 27, 2025

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Here are 5 ASX biotechs expecting clinical trial results in the next few months! Dimerix (ASX:DXB) Dimerix is in the middle of a Phase III trial or its DMX-200 drug for a condition known as Focal Segmental Glomerulosclerosis (FSGS). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can…

ByNick SundichAugust 27, 2025

6 of the best annual results on the ASX in FY25 and 6 of the worst!

Each reporting season, we like to recap some of the best annual results on the ASX and some of the worst as well. Amidst all the companies, it is easy for investors to get lost amidst the mire of information. And so we like to single out particular companies that impressed and others that did…

ByNick SundichAugust 26, 2025

As ASX Reporting Season for FY25 Looms: Here’s An Investors Ultimate Guide

ASX Reporting Season is almost upon us once again. It is the most important time of the year for investors, a time many reconsider if their thesis still holds, many choose to buy into a stock or sell, some will receive dividends (either expectedly or unexpectedly) whilst others will be disappointed. While you may not…

ByNick SundichJuly 23, 2025

Is it possible for an investor to ‘time the market’ or is it just a myth?

Is it possible at all to time the market? Some will tell you it is possible, but they were probably just lucky and/or were not even trying to. Others will tell you it is not possible, but they are most likely trying to find an excuse to blame poor short-term performance. Let's take a serious look…

ByNick SundichJuly 21, 2025

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the ASX generally, or perhaps the investment strategy of buying these worst performing shares at the start of a new year (either a calendar or financial year), thinking they will rebound. Many will be considering this strategy,…

ByNick SundichJuly 14, 2025

Percheron Therapeutics (ASX:PER) picks itself up in 2025

Percheron Therapeutics (ASX:PER) It's a fact of life in the biotech game: drugs often fail in clinical development. Percheron Therapeutics (ASX:PER) had one of those failures late last year. It was working on Avicursen for the treatment of Duchenne Muscular Dystrophy and had reason to believe from earlier work that the drug had potential to…

ByStuart RobertsJuly 7, 2025